Alto Neuroscience (ANRO) Gains from Investment Securities (2023 - 2025)
Alto Neuroscience (ANRO) posted Gains from Investment Securities of $41000.0 for Q1 2025, down 24.07% sequentially from $54000.0 in Q4 2024, and down 83.13% YoY from $243000.0 in Q1 2024.
Alto Neuroscience (ANRO) Gains from Investment Securities (2023 - 2025) Analysis & Trends
Alto Neuroscience has reported Gains from Investment Securities for 3 years, with the latest figure at $41000.0 in Q1 2025.
- Quarterly Gains from Investment Securities fell 83.13% year-over-year to $41000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $95000.0 (up 135.06% YoY) and the FY2024 annual result came in at $297000.0, up 156.57% from the prior year.
- Gains from Investment Securities fell to $41000.0 in Q1 2025 per ANRO's latest filing, from $54000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $243000.0 in Q1 2024 and troughed at -$226000.0 in Q3 2023.
- A 3-year average of -$26714.3 and a median of -$11000.0 in 2023 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities soared 2309.09% in 2024, then plunged 83.13% in 2025.
- Over 3 years, Gains from Investment Securities stood at -$166000.0 in 2023, then soared by 132.53% to $54000.0 in 2024, then decreased by 24.07% to $41000.0 in 2025.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered $41000.0, $54000.0, and $243000.0 for Q1 2025, Q4 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 41,000.00 |
| Mar 31, 2025 | 41,000.00 |
| Dec 31, 2024 | 54,000.00 |
| Dec 31, 2024 | 54,000.00 |
| Mar 31, 2024 | 243,000.00 |
| Mar 31, 2024 | 243,000.00 |
| Dec 31, 2023 | -166,000.00 |
| Dec 31, 2023 | -166,000.00 |
| Sep 30, 2023 | -226,000.00 |
| Sep 30, 2023 | -226,000.00 |
| Jun 30, 2023 | -122,000.00 |
| Jun 30, 2023 | -122,000.00 |
| Mar 31, 2023 | -11,000.00 |
| Mar 31, 2023 | -11,000.00 |